Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ondansetron
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-22 of 22 for your search:
Start Over
Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
Phase: Phase IV
Type: Supportive care
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 2011348-01H, NCT01913990
Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069401, U10CA037420, URCC U1902, URCC-0114, NCI-5857, NCI-P02-0223, NCT00040742
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068205, NCCTG-989201, NCI-P00-0168, NCT00006348
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068694, URCC-U3901, NCI-P01-0180, NCT00020657
Phase III Study of Ondansetron vs Droperidol for the Treatment of Immunotherapy-Induced Emesis (Summary Last Modified 03/92)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-92-C-0043, NCI-T91-0277N, T91-0277
Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: SC19, CAN-NCIC-SC19, CDR0000068627, NCT00016380
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066969, URCC-U3997, NCI-V99-1528, NCT00003817
Phase II Study of CDDP/CBDCA with Ondansetron or Granisetron and G-CSF in Patients with Stage III/IV Epithelial Ovarian Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: no age specified
Sponsor: Other
Protocol IDs: NBSG-9204, NCI-V92-0153
Phase II Study of CDDP/CTX/DOX with G-CSF and Ondansetron in Patients with Metastatic or Recurrent Adenocarcinoma of the Endometrium
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBSG-9206, NCI-V92-0158
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Phase: Phase II
Type: Supportive care
Status: Temporarily closed
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: Rafa protocol THC002/NVP, NCT00285051
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
Phase: No phase specified
Type: Educational/Counseling/Training
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067996, URCC-3996, NCI-P00-0160, NCT00005994
Open-Label Evaluation of a Single Intravenous Dose of GR 38032F for the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin (Summary Last Modified 06/89)
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-88145, NCI-V89-0049
Pilot Open-Label Study of Intravenous Ondansetron/Dexamethasone in Patients with Nausea and Vomiting Associated with Multiple-Day Cisplatin Chemotherapy (Summary Last Modified 11/92)
Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 to 90
Sponsor:
Protocol IDs: MSKCC-91068, NCI-V91-0166
Evaluation of MDLO (Metoclopramide/Dexamethasone/Lorazepam/Ondansetron) for the Prevention of Acute Vomiting In Cancer Patients Receiving High-Dose Cisplatin (Summary Last Modified 11/92)
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-91072, NCI-V91-0180
Randomized, Double-Blind, Comparative Study of Oral RG 12915 vs Intravenous Ondansetron for the Control of Acute and Delayed Vomiting Following High-Dose CDDP (Summary Last Modified 10/92)
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-92020A1, NCI-V92-0115
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6140, NCI-2010-00801, UWCC-6140, UWCC-UW-6140, UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000445452, OHSU-HEM-03074-L, OHSU-1057, MERCK-OHSU-HEM-03074-L, NCT00248547
Start Over